Blood tests are among the most common tools in medicine. Scientists are working to make blood cell imaging faster and more intuitive so that doctors can make fast and accurate diagnostic decisions.
BEAVERTON, Ore., Oct. 24, 2025 /PRNewswire/ — YorLabs, Inc., a medical technology company pioneering next-generation intracardiac imaging solutions for electrophysiology (EP) and interventional cardiology (IC) procedures, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s YorLabs Intracardiac Imaging System – a first-of-its-kind, zero-capex ultrasound platform designed to simplify workflow, reduce cost, and enhance procedural efficiency inside the cath lab.
The tool integrates with the current laboratory infrastructure, captures images of embryos and creates an AI score.
The device has shown to be advantageous for individuals with neurological or orthopaedic disorders.
The expanded FDA clearance makes NeurAxis’ IB-Stim the first FDA approval for a treatment that specifically addresses functional dyspepsia.
Novel technology delivers enhanced image contrast and resolution for confident decisions